SOCS2: Inhibitor of JAK2V617F-mediated signal transduction

Leukemia

Volumn 22, Issue 12, 2008, Pages 2169-2175

  Quentmeier, H ^a   Geffers, R ^b   Jost, E ^c   MacLeod, R A F ^a   Nagel, S ^a   Rohrs S ^a   Romani, J ^a   Scherr, M ^d   Zaborski, M ^a   Drexler, H G ^a  

^a LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; JANUS KINASE 2; PHENYLALANINE; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 2; TRANSCRIPTION FACTOR; VALINE;

ARTICLE; CELL LINE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; HEMATOLOGIC MALIGNANCY; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 57949086449     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.226     Document Type: Article

References (30)

1. Starr R, Willson TA, Viney EM, Murray LJL, Rayner JR, Jenkins BJ et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997; 387: 917-921.
2. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K et al A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997; 387: 921-924.
3. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A et al Structure and function of a new STAT-induced STAT inhibitor. Nature 1997; 387: 924-929.
4. Sutherland KD, Lindeman GJ, Choong DYH, Wittlin S, Brentzell L, Phillips W et al. Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 2004; 23: 7726-7733.
5. Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG et al. DNA methylation changes in multiple myeloma. Leukemia 2004; 18 1687-1692.
6. Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol 2006; 126 422-431.
7. Lee TL, Yeh J, van Waes C, Chen Z. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/ or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 2006; 5: 8-19.
8. Niwa Y, Kanda H, Shikauchi Y, Saiura Y, Matsubara K, Kitagawa T et al Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2006; 24: 6404-6417.
9. Brakensiek K, Länger F, Schlegelberger B, Kreipe H, Lehmann U. Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br J Haematol 2005; 130: 209-217.
10. Jost E, do ÓN, Dahl E, Maintz CE, Jousten P, Habets L et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL1-negative myeloproliferative disorders. Leukemia 2007; 21: 505-510.
11. Etienne A, Carbuccia N, Adelaide J, Bekhouche I, Remy V, Sohn C et al Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. Cancer Genet Cytogenet 2007; 176: 80-88.
12. Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 2005; 102: 18962-18967.
13. Lu X, Huang LJS, Lodish HF. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem 2008; 283: 5258-5266.
14. Quentmeier H, MacLeod RAF, Zaborski M, Drexler HG. JAK2V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006; 20: 471-476.
15. Morgan DA, Gumucio DL, Brodsky I. Granulocyte-macrophage colony-stimulating factor-dependent growth and erythropoietin-induced differentiation of a human cell line MB-02. Blood 1991; 78: 2860-2871.
16. Hu ZB, MacLeod RAF, Meyer C, Quentmeier H, Drexler HG. New acute myeloid leukemia-derived cell line: MUTZ-8 with 5q-. Leukemia 2002; 16 1556-1561.
17. Matozaki S, Nakagawa T, Kawaguchi R, Aozaki R, Tsutsumi M, Murayama T et al. Establishment of a myeloid leukaemic cell line (SKNO-1) from a patient with t(8;21) who acquired monosomy 17 during disease progression. Br J Haematol 1995; 89: 805-811.
18. Fiedler W, Henke RP, Ergün S, Schumacher U, Gehling UM, Vohwinkel G et al. Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome. Cancer 2000; 88: 344-351.
19. Drexler HG. The Leukemia-Lymphoma Cell Line Factsbook. Academic Press: San Diego, CA, 2000.
20. Quentmeier H, Drexler HG, Fleckenstein D, Zaborski M, Armstrong A, Sims JE et al. Cloning of human thymic stromal lymphopoietin (TSLP) and signaling mechanisms leading to proliferation. Leukemia 2001; 15: 1286-1292.
21. MacLeod RAF, Kaufmann M, Drexler HG. Cytogenetic harvesting of commonly used tumor cell lines. Nat Protoc 2007; 2: 372-382.
22. Scherr M, Battmer K, Ganser A, Eder M. Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle 2003; 3: 251-257.
23. Scherr M, Battmer K, Blömer U, Schiedlmeier B, Ganser A, Grez M et al. Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID-repopulating cells. Blood 2002; 99: 709-712.
24. Levine RL, Madleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP et al Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
25. Larsen L, Röpke C. Suppressors of cytokine signalling: SOCS. Acta Pathol Microbiol Immunol Scand 2002; 110: 833-844.
26. Usenko T, Eskinazi D, Correa PN, Amato D, Ben-David Y, Axelrad AA. Overexpression of SOCS-2 and SOCS-3 genes reverses erythorid overgrowth and IGF-I hypersensitivity of primary polycythemia vera (PV) cells. Leuk Lymphoma 2007; 48: 134-146.
27. Tannahill GM, Elliott J, Barry AC, Hibbert L, Cacalano NA, Johnston JA. SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation. Mol Cell Biol 2005; 25: 9115-9126.
28. Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, Vainchenker W et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 2007; 109: 4924-4929.
29. Jegalian AG, Wu H. Differential roles of SOCS family members in EpoR signal transduction. J Interferon Cytokine Res 2002; 22: 853-860.
30. Rice KL, Hormaeche I, Licht JD. Epigenetic regulation of normal and malignant hematopoiesis. Oncogene 2007; 26: 6697-6714.